NZ748260A - Substituted pyrimidine bmi-1 inhibitors - Google Patents
Substituted pyrimidine bmi-1 inhibitorsInfo
- Publication number
- NZ748260A NZ748260A NZ748260A NZ74826013A NZ748260A NZ 748260 A NZ748260 A NZ 748260A NZ 748260 A NZ748260 A NZ 748260A NZ 74826013 A NZ74826013 A NZ 74826013A NZ 748260 A NZ748260 A NZ 748260A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bmi
- substituted pyrimidine
- inhibitors
- inhibit
- level
- Prior art date
Links
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 title abstract 5
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 241000713869 Moloney murine leukemia virus Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872091P | 2013-08-30 | 2013-08-30 | |
| NZ718055A NZ718055A (en) | 2013-08-30 | 2013-11-21 | Substituted pyrimidine bmi-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ748260A true NZ748260A (en) | 2020-01-31 |
Family
ID=52587180
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ748260A NZ748260A (en) | 2013-08-30 | 2013-11-21 | Substituted pyrimidine bmi-1 inhibitors |
| NZ718055A NZ718055A (en) | 2013-08-30 | 2013-11-21 | Substituted pyrimidine bmi-1 inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ718055A NZ718055A (en) | 2013-08-30 | 2013-11-21 | Substituted pyrimidine bmi-1 inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10370371B2 (OSRAM) |
| EP (1) | EP3039015B1 (OSRAM) |
| JP (2) | JP6524094B2 (OSRAM) |
| KR (1) | KR102232595B1 (OSRAM) |
| CN (1) | CN105683166B (OSRAM) |
| AR (1) | AR093580A1 (OSRAM) |
| AU (2) | AU2013399092A1 (OSRAM) |
| CA (1) | CA2922657C (OSRAM) |
| CL (1) | CL2016000466A1 (OSRAM) |
| EA (1) | EA034866B1 (OSRAM) |
| IL (1) | IL244321B (OSRAM) |
| MX (1) | MX370588B (OSRAM) |
| NZ (2) | NZ748260A (OSRAM) |
| TW (1) | TWI692477B (OSRAM) |
| WO (1) | WO2015030847A1 (OSRAM) |
| ZA (1) | ZA201601697B (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6524094B2 (ja) * | 2013-08-30 | 2019-06-05 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換ピリミジンＢｍｉ−１阻害剤 |
| GB201321736D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2017068412A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| KR102720461B1 (ko) | 2016-01-22 | 2024-10-21 | 잔센파마슈티카엔.브이. | Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체 |
| SI3405196T1 (sl) | 2016-01-22 | 2020-03-31 | Janssen Pharmaceutica Nv | Novi substituirani derivati cianoindolina kot inhibitorji NIK |
| KR20220130249A (ko) | 2016-05-26 | 2022-09-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | Egfr 억제제 화합물 |
| CA3027416A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as nik inhibitors |
| ES2837157T3 (es) | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| US10793551B2 (en) | 2017-10-19 | 2020-10-06 | Effector Therapeutics Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
| EP3784664B1 (en) | 2018-04-26 | 2025-02-19 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| EP3813784B1 (en) * | 2018-06-07 | 2024-01-10 | The Regents Of The University Of Michigan | Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith |
| US12023335B2 (en) | 2018-08-17 | 2024-07-02 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020176610A1 (en) * | 2019-02-28 | 2020-09-03 | Ptc Therapeutics, Inc. | Method for treating a multiple myeloma |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US20220296595A1 (en) | 2019-05-05 | 2022-09-22 | Qilu Regor Therapeutics Inc. | Cdk inhibitors |
| JP2022539849A (ja) * | 2019-07-10 | 2022-09-13 | オーセントラ セラピュティクス ピーティーワイ エルティーディー | 治療薬としての４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－Ｎ－（ピリジニル）ピリミジン－２－アミンの誘導体 |
| US20220267320A1 (en) * | 2019-07-24 | 2022-08-25 | Merck Patent Gmbh | 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives |
| PH12022550361A1 (en) | 2019-08-14 | 2023-02-27 | Incyte Corp | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| JP7693656B2 (ja) | 2019-10-11 | 2025-06-17 | インサイト・コーポレイション | Ｃｄｋ２阻害剤としての二環式アミン |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| WO2023250439A1 (en) * | 2022-06-22 | 2023-12-28 | Tempest Therapeutics, Inc. | Trex1 inhibitors and uses thereof |
| US12338248B2 (en) | 2023-07-21 | 2025-06-24 | Accutar Biotechnology Inc. | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (OSRAM) | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| WO1993006866A2 (en) | 1991-10-07 | 1993-04-15 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction |
| CN1102144C (zh) | 1994-08-13 | 2003-02-26 | 株式会社柳韩洋行 | 新的嘧啶衍生物及其制备方法 |
| IN188411B (OSRAM) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| KR100272471B1 (ko) | 1998-11-17 | 2000-11-15 | 김선진 | 신규의 피리미딘 유도체 및 그의 제조방법 |
| ATE253915T1 (de) * | 1999-06-30 | 2003-11-15 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| CA2386218A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| EP1224185B1 (en) * | 1999-10-27 | 2005-11-30 | Novartis AG | Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use |
| CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
| AU4262901A (en) * | 2000-03-29 | 2001-10-08 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DE60136731D1 (de) | 2000-09-20 | 2009-01-08 | Ortho Mcneil Pharm Inc | Pyrazine derivate als tyrosin kinase modulatoren |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| CN100415744C (zh) | 2001-02-20 | 2008-09-03 | 阿斯特拉曾尼卡有限公司 | 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶 |
| EP1364212B1 (en) | 2001-03-02 | 2011-02-02 | GPC Biotech AG | Three hybrid assay system |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| ATE337312T1 (de) * | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
| WO2003011837A1 (en) * | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2003246100A1 (en) | 2002-06-28 | 2004-01-19 | Nippon Shinyaku Co., Ltd. | Amide derivative |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| WO2004007407A2 (en) | 2002-07-11 | 2004-01-22 | Fluorous Technologies Incorporated | Fluorous tagging and scavenging reactants and methods of synthesis and use thereof |
| US20040110821A1 (en) | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| EP1551842A1 (en) | 2002-10-15 | 2005-07-13 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| GB2432834A (en) | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
| EP1713793A4 (en) * | 2004-02-04 | 2009-09-02 | Smithkline Beecham Corp | PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS |
| EP2332940B1 (en) | 2004-03-30 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| JP2006045119A (ja) | 2004-08-04 | 2006-02-16 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| AU2006219231B2 (en) | 2005-02-28 | 2010-01-14 | Japan Tobacco Inc. | Novel aminopyridine compound with Syk inhibitory activity |
| US20110098301A1 (en) | 2005-03-10 | 2011-04-28 | Bayer Healthcare Llc | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders |
| BRPI0713328A2 (pt) | 2006-06-22 | 2012-10-30 | Biovitrum Ab | derivados de piridina e pirazina como inibidores de cinase mnk |
| AU2007304195A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| CN101516873A (zh) | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| CN101679432B (zh) | 2006-10-19 | 2015-04-22 | 西格诺药品有限公司 | 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途 |
| BRPI0720635A2 (pt) | 2006-12-22 | 2014-01-07 | Novartis Ag | Compostos orgânicos e seus usos |
| TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
| GB0714573D0 (en) | 2007-07-26 | 2007-09-05 | Imp Innovations Ltd | Marker gene |
| EP2203436A1 (en) | 2007-09-17 | 2010-07-07 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| WO2009064835A1 (en) * | 2007-11-16 | 2009-05-22 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| ATE524459T1 (de) * | 2007-12-07 | 2011-09-15 | Novartis Ag | Pyrazolederivate und ihr einsatz als hemmer von cyclinabhängigen kinasen |
| DE102008005493A1 (de) | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
| GB0801416D0 (en) * | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| EP2306836B1 (en) * | 2008-07-01 | 2016-09-07 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
| CN102177154A (zh) | 2008-09-02 | 2011-09-07 | 神经研究公司 | 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用 |
| TW201028399A (en) | 2008-11-27 | 2010-08-01 | Shionogi & Co | Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity |
| MX2011008444A (es) | 2009-02-12 | 2011-09-06 | Astellas Pharma Inc | Derivado de heteroanillo. |
| BRPI1013600A2 (pt) | 2009-03-27 | 2019-09-24 | Pathway Therapeutics Inc | "sulfonamidas de pirimidinila e benzintoazol de 1,3,5-triazinila e seu uso em terapia de câncer" |
| CA2763624A1 (en) | 2009-05-27 | 2010-12-02 | Abbott Laboratories | Pyrimidine inhibitors of kinase activity |
| US20110039873A1 (en) * | 2009-06-08 | 2011-02-17 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| KR101903354B1 (ko) | 2009-06-17 | 2018-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| CA2987503C (en) | 2009-07-07 | 2019-02-26 | Mei Pharma, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| EP2454257B1 (en) | 2009-07-15 | 2013-08-21 | AbbVie Inc. | Pyrrolopyridine inhibitors of kinases |
| JP5415176B2 (ja) | 2009-08-06 | 2014-02-12 | 株式会社マキタ | スイッチ |
| ES2539170T3 (es) | 2010-01-12 | 2015-06-26 | Ab Science | Inhibidores de quinasas de oxazol |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| AU2011290189B8 (en) | 2010-08-10 | 2015-02-19 | Astellas Pharma Inc. | Heterocyclic compound |
| PE20131377A1 (es) | 2010-09-13 | 2013-11-30 | Novartis Ag | Triazina-oxadiazoles |
| US20140088056A1 (en) | 2010-09-28 | 2014-03-27 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| EP2796456A1 (en) | 2010-12-09 | 2014-10-29 | Amgen Inc. | Bicyclic compounds as Pim inhibitors |
| IN2013MN01519A (OSRAM) * | 2011-02-25 | 2015-06-12 | Yuhan Corp | |
| CA2840883C (en) | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| TWI623531B (zh) | 2012-11-21 | 2018-05-11 | Ｐｔｃ治療公司 | 經取代反向嘧啶ｂｍｉ－１抑制劑 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| JP6524094B2 (ja) * | 2013-08-30 | 2019-06-05 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換ピリミジンＢｍｉ−１阻害剤 |
-
2013
- 2013-11-21 JP JP2016538906A patent/JP6524094B2/ja not_active Expired - Fee Related
- 2013-11-21 MX MX2016002642A patent/MX370588B/es active IP Right Grant
- 2013-11-21 EP EP13892399.0A patent/EP3039015B1/en not_active Not-in-force
- 2013-11-21 NZ NZ748260A patent/NZ748260A/en not_active IP Right Cessation
- 2013-11-21 NZ NZ718055A patent/NZ718055A/en not_active IP Right Cessation
- 2013-11-21 WO PCT/US2013/071216 patent/WO2015030847A1/en not_active Ceased
- 2013-11-21 CN CN201380080643.5A patent/CN105683166B/zh not_active Expired - Fee Related
- 2013-11-21 TW TW102142556A patent/TWI692477B/zh not_active IP Right Cessation
- 2013-11-21 AU AU2013399092A patent/AU2013399092A1/en not_active Abandoned
- 2013-11-21 CA CA2922657A patent/CA2922657C/en active Active
- 2013-11-21 KR KR1020167008197A patent/KR102232595B1/ko not_active Expired - Fee Related
- 2013-11-21 EA EA201690502A patent/EA034866B1/ru not_active IP Right Cessation
- 2013-11-21 US US14/914,909 patent/US10370371B2/en active Active
- 2013-11-21 AR ARP130104301A patent/AR093580A1/es active IP Right Grant
-
2016
- 2016-02-28 IL IL244321A patent/IL244321B/en active IP Right Grant
- 2016-02-29 CL CL2016000466A patent/CL2016000466A1/es unknown
- 2016-03-11 ZA ZA2016/01697A patent/ZA201601697B/en unknown
-
2018
- 2018-11-27 AU AU2018271277A patent/AU2018271277B2/en not_active Ceased
- 2018-12-14 JP JP2018234524A patent/JP6728321B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ748260A (en) | Substituted pyrimidine bmi-1 inhibitors | |
| NZ708909A (en) | Substituted reverse pyrimidine bmi-1 inhibitors | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| PH12015501934B1 (en) | New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
| MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
| PH12015500263A1 (en) | New bicyclic derivatives | |
| PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
| MX372962B (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| MX2016001011A (es) | Derivados de quinazolin-4-ona sustituida. | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
| MY169267A (en) | New aryl-quinoline derivatives | |
| MX2015017156A (es) | Inhibidores de bace. | |
| NZ742952A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| PH12015502462A1 (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
| MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
| PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors | |
| PH12018500407A1 (en) | New bicyclic compounds as dual atx/ca inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2021 BY IPAN GMBH Effective date: 20201104 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2022 BY ANAQUA SERVICES Effective date: 20211020 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2023 BY ANAQUA SERVICES Effective date: 20221022 |
|
| LAPS | Patent lapsed |